Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04484818
Title Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
Recruitment Active, not recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors ECOG-ACRIN Cancer Research Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.